ERBB2 and breast carcinoma: Improving early access to high-quality, evidence-based therapies is crucial to advancing health outcomes for all individuals with breast cancer.45 Further study of barriers to accessing ERBB2-targeted therapies is needed to target interventions that address determinants at various levels, including health and social policy, research infrastructure, clinician, and patient,45 and ensure that implementation of guideline-recommended breast cancer therapy is equitable from its initial availability.